These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29589987)

  • 1. Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    Kalemkerian GP; Narula N; Kennedy EB
    J Oncol Pract; 2018 May; 14(5):323-327. PubMed ID: 29589987
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
    Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
    J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline.
    Rekhtman N; Leighl NB; Somerfield MR
    J Oncol Pract; 2015 Mar; 11(2):135-6. PubMed ID: 25515718
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    Arch Pathol Lab Med; 2018 Mar; 142(3):321-346. PubMed ID: 29355391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].
    Moldvay J; Peták I
    Magy Onkol; 2012 Mar; 56(1):38-49. PubMed ID: 22403761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Aisner DL; Arcila ME; Beasley MB; Bernicker EH; Colasacco C; Dacic S; Hirsch FR; Kerr K; Kwiatkowski DJ; Ladanyi M; Nowak JA; Sholl L; Temple-Smolkin R; Solomon B; Souter LH; Thunnissen E; Tsao MS; Ventura CB; Wynes MW; Yatabe Y
    J Thorac Oncol; 2018 Mar; 13(3):323-358. PubMed ID: 29396253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies.
    Bernicker EH
    Arch Pathol Lab Med; 2019 Sep; 143(9):1089-1092. PubMed ID: 31100016
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors in lung cancer.
    Thomas A; Rajan A; Giaccone G
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):589-605, viii. PubMed ID: 22520981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
    Brose MS
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
    [No Abstract]   [Full Text] [Related]  

  • 12. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 13. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
    Levitzki A; Klein S
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
    Hanna N; Johnson D; Temin S; Masters G
    J Oncol Pract; 2017 Dec; 13(12):832-837. PubMed ID: 28850309
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
    Rosell R; Karachaliou N; Wolf J; Ou SH
    Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
    [No Abstract]   [Full Text] [Related]  

  • 19. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 20. The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.
    Xie J; Zhang X
    J Genet Genomics; 2016 Jan; 43(1):3-10. PubMed ID: 26842989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.